Search Results Label

Seqirus has been on the front line of pandemic preparedness for more than a century. Learn more about our rapid vaccine production capabilities.

https://www.seqirus.com/expertise/influenza/pandemic-response-solutions

Seqirus is one of the largest influenza vaccine companies in the world, with state-of-the-art manufacturing facilities on three continents. Learn more.

https://www.seqirus.com/manufacturing/global-manufacturing-network

Seqirus brings multifaceted expertise to influenza prevention, employing both egg and cell-based technologies to meet the global community's needs.

https://www.seqirus.com/expertise

First doses of Seqirus’s enhanced influenza vaccine, destined for the U.K., come off a new high-speed fill-and-finish line in Liverpool.

https://www.seqirus.com/news/high-speed-fill-and-finish-in-liverpool

Seqirus appoints Roberta Duncan as new program lead to drive sa-mRNA technology advancement. Accelerates development of sa-mRNA vaccine candidates for seasonal and pandemic influenza.

https://www.seqirus.com/news/seqirus-invests-in-self-amplifying-messenger-rna-technology

The company is prepared to meet the record levels of demand seen during the 2020/21 influenza season amidst the ongoing COVID-19 pandemic

https://www.seqirus.com/news/first-shipment-2021-22

Seqirus announced today that the accelerated development of cell-based manufacturing technology at its manufacturing facility in Holly Springs, North Carolina, has delivered a four-fold increase in seasonal influenza vaccine output in just two years, strengthening the United States’ capacity to respond to pandemic threats.

https://www.seqirus.com/news/seqirus-announces-major-advances-in-pandemic-preparedness

Seqirus, as a member of the CSL group, is bound by CSL's Code of Responsible Business Practice. Access our annual financial and diversity disclosures.

https://www.seqirus.com/our-company/corporate-responsibility/disclosures

Seqirus Presents New Late-Breaking Data at ESWI 2020

https://www.seqirus.com/news/seqirus-presents-new-late-breaking-data-at-eswi-2020

Seqirus Presents Real-World Data for Cell-Based Quadrivalent Seasonal Influenza Vaccine (QIVc) at ESWI 2020

https://www.seqirus.com/news/seqirus-presents-real-world-data-for-cell-based-quadrivalent